Sun Pharmaceutical Industries Limited announced that it has launched FluGuard (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India.
Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.
Commenting on the launch, Kirti Ganorkar, CEO of India Business, Sun Pharma said, “With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching FluGuard® at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India’s pandemic response.”
The company will work closely with the government and medical community to ensure the availability of FluGuard to patients across the country. The stocks of FluGuard will be available in the market from this week.
Sun Pharma is the fourth largest speciality generic pharmaceutical company in the world and one of the top pharma companies in India.
Sun Pharma recently posted its Q1 earnings for FY21. ET NOW spoke to the management of Sun Pharma. In Q1 FY21, the company’s consolidated sales from operations stood at Rs 7,467 crores, a decline of about 9.6% over the same quarter last year. Sales were lead by India business with a growth of 3.2% at Rs 2388 crores.
Sun Pharma management is awaiting next steps from USFDA on desktop audit; they are also expecting the speciality portfolio to pick up. The tax rate in FY21 may jump higher than FY20 which was at 16%, the management said. They are also expecting a clinical trial of two potential COVID-19 treatment drugs.
About Sun Pharmaceutical Industries Limited.
Sun Pharma is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D.